The Role of Microstructure in Topical Drug Product Development

Following the Semi-solid Microstructure Workshop sponsored by BASF and hosted by the Rutgers Center for Dermal Research, a pharmaceutical product development working group was formed. The group, known as the Q3 Working Group, selected the following five areas of focus: Particle/Globule Size and Dist...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Langley, Nigel (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Michniak-Kohn, Bozena (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Osborne, David W. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2019.
Έκδοση:1st ed. 2019.
Σειρά:AAPS Advances in the Pharmaceutical Sciences Series, 36
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04431nam a2200517 4500
001 978-3-030-17355-5
003 DE-He213
005 20190807151448.0
007 cr nn 008mamaa
008 190807s2019 gw | s |||| 0|eng d
020 |a 9783030173555  |9 978-3-030-17355-5 
024 7 |a 10.1007/978-3-030-17355-5  |2 doi 
040 |d GrThAP 
050 4 |a RS380 
050 4 |a RS190-210 
072 7 |a TDCW  |2 bicssc 
072 7 |a MED072000  |2 bisacsh 
072 7 |a TDC  |2 thema 
082 0 4 |a 615.19  |2 23 
245 1 4 |a The Role of Microstructure in Topical Drug Product Development  |h [electronic resource] /  |c edited by Nigel Langley, Bozena Michniak-Kohn, David W. Osborne. 
250 |a 1st ed. 2019. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2019. 
300 |a XIV, 199 p. 102 illus., 57 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a AAPS Advances in the Pharmaceutical Sciences Series,  |x 2210-7371 ;  |v 36 
505 0 |a Part I - Critical Quality Attributes: 1. Rheological Characterization in the Development of Topical Drug Products -- 2. In Vitro Release & Permeation Tests as Critical Quality Attributes in Topical Product Development -- 3. Determination of Particle Size and Microstructure in Topical Pharmaceuticals -- Part II - Role of API and Excipients: 4. Quality Assessment of API in Semisolid Topical Drug Products -- 5. The Role of Excipients in the Microstructure of Topical Semi-solid Drug Products. 
520 |a Following the Semi-solid Microstructure Workshop sponsored by BASF and hosted by the Rutgers Center for Dermal Research, a pharmaceutical product development working group was formed. The group, known as the Q3 Working Group, selected the following five areas of focus: Particle/Globule Size and Distribution, Viscosity/Rheology/Spreadability, In Vitro Testing, State of API, State of Excipients. A committee was appointed for each of these five areas. The committees were tasked to review the literature, identify best practices, list experimental details required for an independent lab to duplicate the test, and propose scientific studies that may meaningfully advance this specific area of focus. Each committee has a chair (or co-chairs) that are the lead author(s) of the chapter. The Q3 Working Group members serve as the critical reviewers of each chapter, making suggestions that improve the quality of the document and that make each of the five chapters uniform in scope and content. Pharmaceutical development scientists that formulate topical products (creams, lotions, gels suspensions, foams, etc) and all the allied raw material suppliers, packaging suppliers, contract laboratories including CROs, CMOs and regulators need access to this book. Overall, the topic of semisolid microstructure is of equal importance to the generic pharmaceutical companies (filing Abbreviated New Drug Applications or ANDAs) and pharmaceutical companies filing New Drug Applications (NDAs). In addition to products applied to the skin, hair, and nails, The Role of Microstructure in Topical Drug Product Development crosses over and is essential reading to developers of oral suspensions, ophthalmic ointments and gels, otic suspension, vaginal semisolids and retention enemas. . 
650 0 |a Pharmaceutical technology. 
650 0 |a Pharmacy. 
650 1 4 |a Pharmaceutical Sciences/Technology.  |0 http://scigraph.springernature.com/things/product-market-codes/B21010 
650 2 4 |a Pharmacy.  |0 http://scigraph.springernature.com/things/product-market-codes/F00008 
700 1 |a Langley, Nigel.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Michniak-Kohn, Bozena.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Osborne, David W.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783030173548 
776 0 8 |i Printed edition:  |z 9783030173562 
776 0 8 |i Printed edition:  |z 9783030173579 
830 0 |a AAPS Advances in the Pharmaceutical Sciences Series,  |x 2210-7371 ;  |v 36 
856 4 0 |u https://doi.org/10.1007/978-3-030-17355-5  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)